Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNOUNCED UPDATED PHASE 2 DATA AT ASCO FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED, ANTI-CTLA-4, DEMONSTRATING DEEP AND DURABLE RESPONSES AND A MEANINGFULLY DIFFERENTIATED SAFETY AND TOLERABILITY PROFILE FOR AN ANTI-CTLA-4 COMBINATION THERAPY

XILIO THERAPEUTICS ANNOUNCES PIPELINE AND BUSINESS UPDATES AND SECOND QUARTER 2025FINANCIAL RESULTS

WALTHAM, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE AUGUST 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 134,000 SHARES OF ITS COMMON STOCK TO TWO NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

WALTHAM, MASS., JULY 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE JULY 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 10,700 SHARES OF ITS COMMON STOCK TO TWO NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDERNASDAQ LISTING RULE 5635(C)(4)

WALTHAM, MASS., JUNE 10, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE APPOINTMENT OF AKINTUNDE (TUNDE) BELLO, PH.D., TO THE COMPANY'S BOARD OF DIRECTORS.

XILIO THERAPEUTICS APPOINTS AKINTUNDE BELLO, PH.D., TO ITS BOARD OF DIRECTORS

TOTAL GROSS PROCEEDS OF UP TO $150.0 MILLION BEFORE THE END OF 2026 IF ALL SERIES B WARRANTS AND SERIES C WARRANTS ARE EXERCISED FOR CASH XILIO MAY ELECT TO CANCEL UNEXERCISED SERIES B OR SERIES C WARRANTS PROPORTIONATELY TO THE AMOUNT OF NON-DILUTIVE CAPITAL RECEIVED, UNDER CERTAIN CIRCUMSTANCES FINANCING CO-LED BY NEW INVESTORS COASTLANDS CAPITAL AND FRAZIER LIFE SCIENCES AND INCLUDED PARTICIPATION FROM GILEAD SCIENCES, INC., LOGOS CAPITAL, SAMSARA BIOCAPITAL AND OTHER NEW AND EXISTING INVESTORS WALTHAM, MASS., JUNE 05, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF PRE-FUNDED WARRANTS AND ACCOMPANYING COMMON STOCK WARRANTS FOR INITIAL GROSS PROCEEDS OF APPROXIMATELY $50.0 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES.

XILIO THERAPEUTICS ANNOUNCES CLOSING OF $50.0 MILLION PUBLIC OFFERING

WALTHAM, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE JUNE 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 181,300 SHARES OF ITS COMMON STOCK TO FIVE NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

WALTHAM, MASS., JUNE 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF PRE-FUNDED WARRANTS TO PURCHASE 66,676,000 SHARES OF COMMON STOCK (THE PRE-FUNDED WARRANTS), ACCOMPANIED BY SERIES A WARRANTS TO PURCHASE 66,676,000 SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS) (THE SERIES A WARRANTS), SERIES B WARRANTS TO PURCHASE 66,676,000 SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS) (THE SERIES B WARRANTS) AND SERIES C WARRANTS TO PURCHASE 66,676,000 SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS) (THE SERIES C WARRANTS). THE COMBINED PUBLIC OFFERING PRICE OF ONE PRE-FUNDED WARRANT, ONE SERIES A WARRANT, ONE SERIES B WARRANT AND ONE SERIES C WARRANT, WHICH ARE BEING SOLD TOGETHER BUT ARE IMMEDIATELY SEPARABLE, IS $0.7499, WHICH IS EQUAL TO THE COMBINED OFFERING PRICE OF THE PRE-FUNDED WARRANTS, SERIES A WARRANTS, SERIES B WARRANTS AND SERIES C WARRANTS, LESS THE $0.0001 PER SHARE EXERCISE PRICE OF THE PRE-FUNDED WARRANTS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 5, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. ALL OF THE SECURITIES ARE BEING OFFERED BY XILIO.

XILIO THERAPEUTICS ANNOUNCES PRICING OF $50.0 MILLION PUBLIC OFFERING

WALTHAM, MASS., JUNE 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT IT IS COMMENCING AN UNDERWRITTEN PUBLIC OFFERING OF PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK ACCOMPANIED BY SERIES A WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS), SERIES B WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS) AND SERIES C WARRANTS TO PURCHASE SHARES OF COMMON STOCK (OR, IN CERTAIN CIRCUMSTANCES, PRE-FUNDED WARRANTS). ALL OF THE SECURITIES TO BE SOLD IN THE PROPOSED OFFERING WILL BE OFFERED BY XILIO. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

XILIO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

26% PRELIMINARY OBJECTIVE RESPONSE RATE OBSERVED IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS CRC) WITHOUT LIVER METASTASES

XILIO THERAPEUTICS ANNOUNCES UPDATED PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER

UPDATED PHASE 2 DATA TO BE PRESENTED AT ASCO FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED, ANTI-CTLA-4, IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH METASTATIC MICROSATELLITE STABLE COLORECTAL CANCER (MSS CRC) ADVANCING MULTIPLE MASKED T CELL ENGAGER PROGRAMS UTILIZING XILIO'S NOVEL ATACR AND SEECR FORMATS, WITH FIRST DEVELOPMENT CANDIDATES ANTICIPATED IN SECOND HALF OF 2025 WALTHAM, MASS., MAY 08, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS,INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED PIPELINE PROGRESS AND BUSINESS UPDATES AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

XILIO THERAPEUTICS ANNOUNCES PIPELINE AND BUSINESS UPDATES AND FIRST QUARTER 2025FINANCIAL RESULTS

WALTHAM, MASS., MAY 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE MAY 1, 2025, THE COMPANY GRANTED A NON-QUALIFIED STOCK OPTION TO PURCHASE 5,000 SHARES OF ITS COMMON STOCK TO ONE NEW EMPLOYEE UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

Xilio Therapeutics, Inc.

XLO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Xilio Therapeutics, Inc.

XLO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XLO